Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2452

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2452). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622452)

The text contains information about Lisdexamfetamine capsules containing 20 mg of lisdexamfetamine dimesylate per capsule. It instructs to dispense the medication guide to each patient and store the capsules within certain temperature excursions. The manufacturer is mentioned as Bryant Ranch Prepack, Inc, and the medication is to be kept out of reach of children.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

FDA Label Image

Figure 1 (Lisdexcaps 02)

Special Population - This text discusses the consideration of specific populations in research or clinical settings. It mentions the evaluation of gender (Male/Female) and age groups ranging from 65 to greater than 75 years. It also includes categories for different levels of renal impairment: Mild, Moderate, Severe, and End-Stage Renal Disease. Additionally, it mentions a "Fold Change and 90% CI" related to a reference point, suggesting a statistical analysis or comparison being conducted.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

This appears to be a list of medications or substances with their corresponding changes in Cmax and AUC values. The text also mentions fold change and a reference point. It seems to be a report or data comparison regarding the impact of these substances on certain parameters.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

This is not-available.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

FDA Label Image

Figure 5 (Lisdexcaps 06)

FDA Label Image

Figure 6 (Lisdexcaps 07)

This is a description of LS Mean (SE) PERMP Total Scores at different time points post-dose for both Phacebo and Lisdexamfetamine. The data presents the scores for each medication at 4, 8, 12, and 14 hours post-dose.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

This is a chart showing the proportion of subjects experiencing relapse or treatment failure over time (in days) in a study involving Lisdexamfetamine. The data is represented as a percentage.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

Not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.